A COMPARATIVE-STUDY OF INTRAVENOUS GRANISETRON VERSUS INTRAVENOUS ANDORAL ONDANSETRON IN THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CHEMOTHERAPY
Jo. Park et al., A COMPARATIVE-STUDY OF INTRAVENOUS GRANISETRON VERSUS INTRAVENOUS ANDORAL ONDANSETRON IN THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CHEMOTHERAPY, American journal of clinical oncology, 20(6), 1997, pp. 569-572
We conducted a prospective, randomized, open, single-center, parallel
group study comparing the anti-emetic efficacy and toxicity of granise
tron with that of ondansetron in patients receiving moderately emetoge
nic chemotherapy. From December 1994 to May 1995, patients who were to
receive moderately emetogenic chemotherapy for the first time or who
had not received chemotherapy (80 to 100 mg/m(2) of cisplatin or 40 mg
/m(2) of doxorubicin) within 4 weeks previously were enrolled in this
study. The following anti-emetic regimens were used: 3 mg of granisetr
on were given intravenously before chemotherapy for a single dose; 8 m
g of ondansetron were given intravenously before chemotherapy and then
every 8 hours for a total of 3 doses, plus 8 mg of an oral maintenanc
e dose every 12 hours for 5 consecutive days. We evaluated 97 patients
(48 received granisetron and 49 received ondansetron). In the first 2
4 hours after chemotherapy, complete and major responses were achieved
in 76.6% of the patients receiving granisetron and in 72.9% of patien
ts receiving ondansetron (p = 0.9033). Additionally, there was no diff
erence in the control of delayed nausea and vomiting between the two g
roups (51.1% versus 54.2%, p = 0.9200), and there were no significant
adverse effects or toxicities. We have concluded that a single dose of
granisetron is as effective in prophylaxis of emesis induced by moder
ately emetogenic chemotherapy as a triple dose of ondansetron plus ora
l maintenance.